HIV-associated lymphoma

Blood

Volumn 115, Issue 15, 2010, Pages 2896-2897

  Levine, Alexandra M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE;

B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL TYPE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HISTOGENESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; LYMPHOCYTE COUNT; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NOTE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIRUS REACTIVATION;

EID: 77951031497     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-262717     Document Type: Note

References (8)

1. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
2. Sparano JA, Lee JY, KaplanLDet al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated, B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008-3016.
3. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653-4659. (Pubitemid 36857717)
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.NEngl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
5. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24(25):4123-4128. (Pubitemid 46622288)
6. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS malignancies consortium trial 010. Blood. 2005;106(5):1538-1543.
7. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA. 1998;279(1):35-40. (Pubitemid 28070548)
8. Koo S, Baden LR. Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy. J Natl Compr Canc Netw. 2008;6(2):202-213. (Pubitemid 351340527)